Literature DB >> 34527903

Diagnostic, treatment and outcome possibilities in achondroplasia.

Simona Bucerzan1, Camelia Alkhzouz1, Mirela Crisan2, Diana Miclea3, Carmen Asavoaie4, Roxana Ilies4, Paula Grigorescu-Sido1.   

Abstract

INTRODUCTION: Achondroplasia is a common form of chondrodysplasia. It is transmitted by autosomal dominant trait. The disease is determined by mutations in receptor-3 gene of the fibroblast growth factor. The most frequent mutations are c.1138G>A and c.1183G>C; c.1138A. The diagnosis can usually be made on the basis of clinical characteristics and specific features on radiographs. It is not necessary to perform molecular testing in every child with a clinical diagnosis of achondroplasia.The aim of this study is to establish the diagnostic, treatment and outcome possibilities in patients with achondroplasia in our care.
METHOD: The study group consisted of 27 patients with achondroplasia. The method consisted of: clinical and radiological examinations. The DNA analasys was performed by PCR-RFLP technique.
RESULTS: 80 patients were diagnosed with bone dysplasia; 24 of them were diagnosed (on clinical and radiological basis) with achondroplasia. Out of this group, 16 patients were identified as heterozygotes for G1138A mutation in FGFR3 gene; 3 patients undergoing treatment with somatotropic hormone; the growth rate is improving from 0.1 cm/month to 0.5 cm/month.
CONCLUSIONS: In achondroplasia diagnosis is based on clinical and radiological criteria. It is the first study that reports the prevelance of this mutation in Romania.

Entities:  

Keywords:  Romania; achondroplasia; child; chondrodysplasia; molecular diagnostic techniques

Year:  2021        PMID: 34527903      PMCID: PMC8411826          DOI: 10.15386/mpr-2222

Source DB:  PubMed          Journal:  Med Pharm Rep        ISSN: 2602-0807


  10 in total

Review 1.  Achondroplasia: Development, pathogenesis, and therapy.

Authors:  David M Ornitz; Laurence Legeai-Mallet
Journal:  Dev Dyn       Date:  2017-03-02       Impact factor: 3.780

2.  Health Supervision for People With Achondroplasia.

Authors:  Julie Hoover-Fong; Charles I Scott; Marilyn C Jones
Journal:  Pediatrics       Date:  2020-06       Impact factor: 7.124

3.  Rapid detection of G1138A and G1138C mutations of the FGFR3 gene in patients with achondroplasia using high-resolution melting analysis.

Authors:  Xiang He; Feng Xie; Zhao-rui Ren
Journal:  Genet Test Mol Biomarkers       Date:  2012-02-17

4.  Molecular defects in achondroplasia and the effects of growth hormone treatment.

Authors:  Y Seino; T Moriwake; H Tanaka; M Inoue; S Kanzaki; T Tanaka; N Matsuo; H Niimi
Journal:  Acta Paediatr Suppl       Date:  1999-02

5.  Achondroplasia in Sweden caused by the G1138A mutation in FGFR3.

Authors:  A Alderborn; M Anvret; K H Gustavson; L Hagenäs; C Wadelius
Journal:  Acta Paediatr       Date:  1996-12       Impact factor: 2.299

Review 6.  Achondroplasia: a comprehensive clinical review.

Authors:  Richard M Pauli
Journal:  Orphanet J Rare Dis       Date:  2019-01-03       Impact factor: 4.123

7.  Genotyping of the G1138A mutation of the FGFR3 gene in patients with achondroplasia using high-resolution melting analysis.

Authors:  Chia-Cheng Hung; Chien-Nan Lee; Chien-Hui Chang; Yuh-Jyh Jong; Chih-Ping Chen; Wu-Shiun Hsieh; Yi-Ning Su; Win-Li Lin
Journal:  Clin Biochem       Date:  2007-09-06       Impact factor: 3.281

Review 8.  Obesity in achondroplasia patients: from evidence to medical monitoring.

Authors:  Celine Saint-Laurent; Laura Garde-Etayo; Elvire Gouze
Journal:  Orphanet J Rare Dis       Date:  2019-11-14       Impact factor: 4.123

Review 9.  Optimal management of complications associated with achondroplasia.

Authors:  Penny J Ireland; Verity Pacey; Andreas Zankl; Priya Edwards; Leanne M Johnston; Ravi Savarirayan
Journal:  Appl Clin Genet       Date:  2014-06-24

Review 10.  The evolving therapeutic landscape of genetic skeletal disorders.

Authors:  Ataf Hussain Sabir; Trevor Cole
Journal:  Orphanet J Rare Dis       Date:  2019-12-30       Impact factor: 4.123

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.